Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.
Zhang L, Balan G, Barreiro G, Boscoe BP, Chenard LK, Cianfrogna J, Claffey MM, Chen L, Coffman KJ, Drozda SE, Dunetz JR, Fonseca KR, Galatsis P, Grimwood S, Lazzaro JT, Mancuso JY, Miller EL, Reese MR, Rogers BN, Sakurada I, Skaddan M, Smith DL, Stepan AF, Trapa P, Tuttle JB, Verhoest PR, Walker DP, Wright AS, Zaleska MM, Zasadny K, Shaffer CL. Zhang L, et al. Among authors: sakurada i. J Med Chem. 2014 Feb 13;57(3):861-77. doi: 10.1021/jm401622k. Epub 2014 Jan 22. J Med Chem. 2014. PMID: 24392688
Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates.
Stepan AF, Claffey MM, Reese MR, Balan G, Barreiro G, Barricklow J, Bohanon MJ, Boscoe BP, Cappon GD, Chenard LK, Cianfrogna J, Chen L, Coffman KJ, Drozda SE, Dunetz JR, Ghosh S, Hou X, Houle C, Karki K, Lazzaro JT, Mancuso JY, Marcek JM, Miller EL, Moen MA, O'Neil S, Sakurada I, Skaddan M, Parikh V, Smith DL, Trapa P, Tuttle JB, Verhoest PR, Walker DP, Won A, Wright AS, Whritenour J, Zasadny K, Zaleska MM, Zhang L, Shaffer CL. Stepan AF, et al. Among authors: sakurada i. J Med Chem. 2017 Sep 28;60(18):7764-7780. doi: 10.1021/acs.jmedchem.7b00604. Epub 2017 Sep 13. J Med Chem. 2017. PMID: 28817277
Development of a novel class of potent and selective FIXa inhibitors.
Zhang T, Andre P, Bateman TJ, Chen YH, Desai K, Ellsworth K, Geissler WM, Guo L, Hruza A, Jian T, Meng D, Parker DL Jr, Qian X, Reichert P, Sherer EC, Shu M, Smith CJ, Sonatore LM, Tschirret-Guth R, Nolting AF, Orr R, Campeau LC, Araki K, Nishimura T, Sakurada I, Wood HB. Zhang T, et al. Among authors: sakurada i. Bioorg Med Chem Lett. 2015 Nov 1;25(21):4945-4949. doi: 10.1016/j.bmcl.2015.04.057. Epub 2015 Apr 29. Bioorg Med Chem Lett. 2015. PMID: 25978966
Discovery of (-)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone--a potent NR2B-selective N-methyl D-aspartate (NMDA) antagonist for the treatment of pain.
Kawai M, Ando K, Matsumoto Y, Sakurada I, Hirota M, Nakamura H, Ohta A, Sudo M, Hattori K, Takashima T, Hizue M, Watanabe S, Fujita I, Mizutani M, Kawamura M. Kawai M, et al. Among authors: sakurada i. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5558-62. doi: 10.1016/j.bmcl.2007.08.014. Epub 2007 Aug 15. Bioorg Med Chem Lett. 2007. PMID: 17766106
Discovery of novel and orally active NR2B-selective N-methyl-D-aspartate (NMDA) antagonists, pyridinol derivatives with reduced HERG binding affinity.
Kawai M, Nakamura H, Sakurada I, Shimokawa H, Tanaka H, Matsumizu M, Ando K, Hattori K, Ohta A, Nukui S, Omura A, Kawamura M. Kawai M, et al. Among authors: sakurada i. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5533-6. doi: 10.1016/j.bmcl.2007.08.039. Epub 2007 Aug 22. Bioorg Med Chem Lett. 2007. PMID: 17768047
Development of a novel tricyclic class of potent and selective FIXa inhibitors.
Meng D, Andre P, Bateman TJ, Berger R, Chen YH, Desai K, Dewnani S, Ellsworth K, Feng D, Geissler WM, Guo L, Hruza A, Jian T, Li H, Metzger J, Parker DL, Reichert P, Sherer EC, Smith CJ, Sonatore LM, Tschirret-Guth R, Wu J, Xu J, Zhang T, Campeau LC, Orr R, Poirier M, McCabe-Dunn J, Araki K, Nishimura T, Sakurada I, Hirabayashi T, Wood HB. Meng D, et al. Among authors: sakurada i. Bioorg Med Chem Lett. 2015 Nov 15;25(22):5437-43. doi: 10.1016/j.bmcl.2015.07.078. Epub 2015 Jul 31. Bioorg Med Chem Lett. 2015. PMID: 26318999
Structure-activity relationship study of novel NR2B-selective antagonists with arylamides to avoid reactive metabolites formation.
Kawai M, Sakurada I, Morita A, Iwamuro Y, Ando K, Omura H, Sakakibara S, Masuda T, Koike H, Honma T, Hattori K, Takashima T, Mizuno K, Mizutani M, Kawamura M. Kawai M, et al. Among authors: sakurada i. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5537-42. doi: 10.1016/j.bmcl.2007.08.033. Epub 2007 Aug 19. Bioorg Med Chem Lett. 2007. PMID: 17766107
Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors.
Sakurada I, Endo T, Hikita K, Hirabayashi T, Hosaka Y, Kato Y, Maeda Y, Matsumoto S, Mizuno T, Nagasue H, Nishimura T, Shimada S, Shinozaki M, Taguchi K, Takeuchi K, Yokoyama T, Hruza A, Reichert P, Zhang T, Wood HB, Nakao K, Furusako S. Sakurada I, et al. Bioorg Med Chem Lett. 2017 Jun 1;27(11):2622-2628. doi: 10.1016/j.bmcl.2017.03.002. Epub 2017 Mar 6. Bioorg Med Chem Lett. 2017. PMID: 28408226
Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
Ueki K, Tanizawa Y, Nakamura J, Yamada Y, Inagaki N, Watada H, Shimomura I, Nishimura R, Miyoshi H, Abiko A, Katagiri H, Hayashi M, Shimada A, Naruse K, Fujimoto S, Fujiwara M, Shikata K, Okada Y, Araki E, Yamazaki T, Kadowaki T; J-BRAND Registry Group. Ueki K, et al. BMJ Open Diabetes Res Care. 2021 Jan;9(1):e001787. doi: 10.1136/bmjdrc-2020-001787. BMJ Open Diabetes Res Care. 2021. PMID: 33441417 Free PMC article.
17 results